 |
| Viekira Pak--Courtesy of AbbVie |
Last week, the FDA came down on AbbVie ($ABBV) for serious liver issues tied to its hep C fighters Viekira Pak and Technivie, calling on the company to update the drugs' labels to warn doctors against using the meds in patients with advanced forms of the disease. Now the Illinois pharma could be facing the music with Express Scripts ($ESRX), as the PBM is planning to hold a meeting to review the news and changes to the drugs' labels. The move could spell disaster for AbbVie, which counts on its exclusive pact with Express Scripts for Viekira Pak to defend market share from Gilead Sciences ($GILD) and its rival meds Harvoni and Sovaldi. More from FiercePharma